Saturday 17 October 2026
Export INMD’s income statement to Excel — free account
InMode Ltd.
INMD Healthcare Medical Devices
InMode Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $370.5 million, down 6.16% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS fell 31.0% and free cash flow fell 12.6%, each against the same quarter a year earlier.
14.16
0.16
−1.12%
Follow INMD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
6.83 | 10.06 | 9.91 | 11.70 |
P/S ratio |
2.59 | 2.56 | 2.32 | 2.30 | |
P/FCF ratio |
9.99 | 11.26 | 10.14 | 10.43 | |
P/Operating CF |
38.54 | 41.87 | 56.37 | 40.91 | |
P/B ratio |
1.34 | 1.39 | 1.27 | 1.26 | |
Price to Tangible BV |
1.34 | 1.39 | 1.27 | 1.26 | |
EV/Sales |
1.13 | 1.06 | 0.88 | 0.96 | |
EV/EBITDA |
4.67 | 4.58 | 4.10 | 5.15 | |
EV/Operating CF |
4.32 | 4.62 | 3.81 | 4.31 | |
EV/FCF |
4.35 | 4.68 | 3.86 | 4.36 | |
Quick Ratio |
8.71 | 8.83 | 7.88 | 7.28 | |
Current Ratio |
9.75 | 9.88 | 8.80 | 8.18 | |
Net Debt/EBITDA |
(25.28) | (21.22) | (52.50) | (40.30) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.48 | 0.48 | 0.51 | 0.52 | |
Operating CF/Net income |
1.12 | 0.84 | 1.33 | 1.23 | |
Capex/Depreciation |
(0.86) | (3.07) | (0.98) | (1.18) | |
Research and Development Expense of Revenue |
3.80% | 3.38% | 4.32% | 3.82% | |
Selling, General and Administrative Expense of Revenue |
51.38% | 49.88% | 58.47% | 58.17% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
2.89% | 2.41% | 3.29% | 3.88% | |
Graham Net Nets |
0.62 | 0.65 | 0.68 | 0.65 | |
Graham Number |
0.00 | 18.63 | 0.00 | 0.00 | |
Earnings Yield |
14.63% | 9.94% | 10.09% | 8.55% | |
Free Cash Flow Yield |
10.01% | 8.88% | 9.86% | 9.58% | |
Revenue per Share |
1.47 | 1.61 | 1.29 | 1.62 | |
Operating CF per Share |
0.39 | 0.35 | 0.24 | 0.36 | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.38 | 0.34 | 0.24 | 0.35 | |
Cash per Share |
8.41 | 8.59 | 8.47 | 8.51 | |
Shareholders Equity per Share |
10.32 | 10.57 | 10.43 | 10.68 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
10.32 | 10.57 | 10.43 | 10.68 | |
Free Cash Flow |
24.33 | 22.14 | 15.21 | 20.84 | |
Working Capital |
597.96 | 627.88 | 603.43 | 570.56 | |
Capital Expenditures |
(0.13) | (0.53) | (0.17) | (0.21) | |
Net Current Asset Value |
585.07 | 615.39 | 591.20 | 558.80 | |
EV/EBIT |
4.71 | 4.62 | 4.14 | 5.20 | |
Capex to Sales |
0.00 | 0.01 | 0.00 | 0.00 | |
Price to Operating Income |
10.81 | 11.12 | 10.87 | 12.44 | |
| Other line items | |||||
Average Receivables |
60.51 | 63.83 | 65.07 | 68.60 | |
Average Payables |
15.25 | 15.85 | 15.95 | 18.14 | |
Average Inventory |
65.48 | 66.80 | 67.59 | 69.89 | |
Average Assets |
760.14 | 776.05 | 727.79 | 714.34 | |
Average Common Equity |
— | 674.68 | — | — |
Columns are period end dates